SCHEMBL2544403

SCHEMBL2544403

C(=N\c1ccc(/N=C/c2ccccc2)c2ccccc12)\c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
DHODH Q02127 1/20 0.50
CHAT P28329 1/20 0.49
MAPT P10636 4/20 0.48
ALDH1A1 P00352 4/20 0.48
KDM4E B2RXH2 3/20 0.48
HPGD P15428 1/20 0.48
CA1 P00915 4/20 0.46
CA2 P00918 4/20 0.46
CA12 O43570 3/20 0.46
CA9 Q16790 3/20 0.46
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
GAA P10253 2/20 0.45
POLB P06746 1/20 0.43
HTT P42858 1/20 0.43
RAB9A P51151 1/20 0.43
BLM P54132 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2544406 1.00 LMNA (0.50) LMNAL3MBTL1DHODHCHATMAPT
SCHEMBL11781793 0.84 CHEK1 (0.44) LMNAL3MBTL1DHODHCHATMAPT
SCHEMBL10799444 0.83 DHODH (0.71) LMNAL3MBTL1DHODHCHATMAPT
SCHEMBL12417102 0.83 DHODH (0.71) LMNAL3MBTL1DHODHCHATMAPT
SCHEMBL5363618 0.83 DHODH (0.71) LMNAL3MBTL1DHODHCHATMAPT
SCHEMBL12633216 0.82 LMNA (0.59) LMNAL3MBTL1DHODHCHATMAPT
SCHEMBL1870853 0.82 LMNA (0.59) LMNAL3MBTL1DHODHCHATMAPT
SCHEMBL1710167 0.82 LMNA (0.59) LMNAL3MBTL1DHODHCHATMAPT
SCHEMBL22299852 0.81 MEN1 (0.50) LMNAL3MBTL1DHODHCHATMAPT
SCHEMBL28320760 0.81 DHODH (0.59) LMNAL3MBTL1DHODHCHATMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2014281-A1 Use of inhibitors of sirtuins and/or ampk for the preparation of a medicament for the treatment of polyalanine diseases. INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2009-01-14 EP claimed
WO-2008155390-A2 USE OF INHIBITORS OF SIRTUINS AND/OR AMPK FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF POLYALANINE DISEASES. INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2008-12-24 WO claimed
US-9168316-B2 Methods for treating obesity GU YANSONG (US) 2015-10-27 US disclosed
US-8980852-B2 Methods for treating obesity GU YANSONG (US) 2015-03-17 US disclosed
US-20140322136-A1 METHODS FOR TREATING OBESITY GU YANSONG (US) 2014-10-30 US disclosed
US-20110262362-A1 METHODS FOR TREATING OBESITY GU YANSONG 2011-10-27 US disclosed
EP-2014281-A1 Use of inhibitors of sirtuins and/or ampk for the preparation of a medicament for the treatment of polyalanine diseases. INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2009-01-14 EP disclosed
WO-2008155390-A2 USE OF INHIBITORS OF SIRTUINS AND/OR AMPK FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF POLYALANINE DISEASES. INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2008-12-24 WO disclosed